Active Stocks
Thu Mar 28 2024 15:59:33
  1. Tata Steel share price
  2. 155.90 2.00%
  1. ICICI Bank share price
  2. 1,095.75 1.08%
  1. HDFC Bank share price
  2. 1,448.20 0.52%
  1. ITC share price
  2. 428.55 0.13%
  1. Power Grid Corporation Of India share price
  2. 277.05 2.21%
Business News/ Companies / News/  Cipla’s Indore factory gets US FDA clearance
BackBack

Cipla’s Indore factory gets US FDA clearance

The US FDA had during an inspection of Cipla's manufacturing facility at Indore's SEZ in July-August 2015 observed manufacturing practice violations

The US FDA clearance is a shot in the arm for Cipla as the company is trying to increase its footprint in the world’s biggest market for pharmaceutical products.Premium
The US FDA clearance is a shot in the arm for Cipla as the company is trying to increase its footprint in the world’s biggest market for pharmaceutical products.

The US Food and Drug Administration (US FDA) has cleared Cipla Ltd’s manufacturing facility at Indore’s special economic zone (SEZ) of manufacturing practice violations that it had observed during an inspection in July-August 2015.

“Cipla has received Establishment Inspection Report (EIR) from the US FDA for its Indore facility indicating formal closure of US FDA inspection conducted in July/August 2015," the company said in a stock exchange notice.

The company’s Goa units, however, came under the regulatory scanner on 30 September.

The US FDA clearance is a shot in the arm for Cipla as the company is trying to increase its footprint in the world’s biggest market for pharmaceutical products, where its penetration is significantly low. North America accounted for about 15% of Cipla’s total sales in 2015-16.

Following the inspection last year, the US drug regulator had issued a Form 483 to the company’s Indore plant with nine observations relating to deviations from good manufacturing practices.

The US FDA issues Form 483 to a facility if the inspectors observe conditions that violate the US Food, Drug & Cosmetic Act.

In a conference call with analysts post the June quarter results, Cipla’s management had indicated that abbreviated new drug applications filed from the Indore plant may not be significant as it was a relatively new manufacturing site.

The pharma company has not received product approvals in the US for those made in the Indore plant since the receipt of the Form 483.

Last month, the US FDA made four observations across Cipla’s three units in Goa after an inspection. The company said these observations were “procedural in nature" and that it had already responded to the regulator’s queries.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 13 Oct 2016, 02:52 AM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App